Articles On Adalta (ASX:1AD)

The CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure cancer. But since the US FDA approved the first cell-gene therapy to treat leukemia in 2018, the technology has not really caught on in the main...

Highlights: AdAlta and Carina Biotech enter a collaboration agreement to develop i-body enabled CAR-T cancer immunotherapies against up to five solid tumour antigen targets Combining Carina’s advanced CAR-T platform technologies with AdAl...

It was another positive close for the Australian bourse today with energy the standout sector. The ASX 200 closed 0.17% higher at 7,503 points while the ASX Emerging Companies Index gained 1.1% to close at 2,262 points. Leading the charge w...

Leading the health stocks today is Nanosonics (ASX:NAN)  up 19.69% after flagging FY21 revenues of $103.1 million, with strong momentum in H2 where revenues came in at $60 million – up 39% from H1. The company installed 3,030 units of its a...

AdAlta Limited (ASX:1AD) and Carina Biotech have announced a collaboration agreement to develop next-generation i-body enabled CAR-T cells.

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Whisky manufacturer Lark Distilling Co (ASX:LRK) kept things warm during winter, leading a group of 25 stocks that posted a 14-day RSI above 70 last week. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relat...

Australian shares have extended gains for the second day in a row, rising by 0.91% despite more COVID cases across states. All 11 sectors were in the green, except for Healthcare. Mining and Energy led the gains, rising by 2% each, buoyed b...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

The Aussie share market has fallen for two consecutive days, down by 0.46% today. Seven sectors were down, while four rose. Utilities and Mining were the worst peforming sectors, while Healtcare and IT were the best. In big cap news today,...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

ShareCafeHidden Gems Webinar Recap OEL, 1AD, HRZ & LRS Catch up on the full webinar with presentations from Otto Energy (ASX:OEL), AdAlta Limited (ASX:1AD), Horizon Minerals Limited (ASX:HRZ) & Latin Resources Limited (ASX: LRS). H...

ShareCafeA new approach to drug discovery Presenter – Tim Oldham – CEO & Managing Director – Adalta Limited is a clinical-stage biotechnology company that uses its i-body platform to discover and develop next-generation protein therape...

Summary The ASX 200 is trading lower by 8.60 points or 0.12% to 7,106.60 at the close, weighed down by energy and mining stocks. The healthcare sector was the worst performer, falling 0.87%, followed by energy, materials, and A-REIT....

AdAlta (ASX:1AD) has announced that its commercial agreement with GE Healthcare is moving to the next phase following the successful identification of multiple i-bodies to be advanced into pre-clinical development for use as a poten...

Summary The ASX 200 trades higher by 15.20 points or 0.22% to 7045.50 at the close, led by gains in heavyweight healthcare and energy stocks. Retail player Kogan.Com and gold miner Silver Lake Resources are top performing stocks on the...

Summary The ASX 200 is set to close the week with narrow gains, led by a strong rally in healthcare and tech stocks. The top five gainers on the ASX are EML Payments, A2 Milk Company, Webjet, Nuix and Xero. Bitcoin staged a smart reco...

Summary The ASX 200 gained 89.50 points or 1.29% to 7021.20 amid broad-based buying. Nine of the 11 sectors traded in the green, while tech stocks lead the pack with a 4.32% gain.  Afterpay emerges as the top gainer, followed by Redbu...

Summary The ASX 200 is heading towards its worst performance since late February, down 2% at 6924.10 at the close. The market breadth was extremely week, with all the 11 sectoral indices trading in red. EML Payments shares plunged ove...

Summary Island Pharmaceuticals and AdAlta have obtained patent protection for their lead programs in the US and Japan, respectively. Paradigm Biopharmaceuticals has received first revenue through a physician prescription of Zilosul®....

Summary Exopharm obtained firm commitments from institutional and sophisticated investors to raise a total of AU$12 million. Race Oncology announced that its new Chief Medical Officer, Dr David Fuller, is set to join on 1 July 2021....

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Source: ShutterstockProfessional Summary Biotech penny stocks are extremely volatile, given the unpredictable nature of the biotechnology industry. Positive clinical developments and regulatory approvals for biotech penny players coul...

The biopharmaceutical discovery and development company, Adalta Ltd [ASX:1AD] share price is higher today, after announcing its product had received Orphan Drug Designation from the US Food and Drug Administration... The post Orphan Status...

The AdAlta Ltd (ASX:1AD) share price is rocketing today following the positive news on its drug trials. In mid-morning trade, the biotech company’s share price is soaring 31.4% higher to 23 cents. However, at the time of writing, the AdAlt...

AdAlta (ASX:1AD) has soared to a one-and-a-half year high after its lead drug candidate — a molecule inspired by shark ... Read More The post AdAlta soars after getting orphan drug designation for its shark-based drug appeared first on Stoc...

The capital raising wave shows no sign of crashing with August’s total coming in at $4.7bn. Once again resources companies raised more than any other sector — $163m of the $296m raised by companies with market capitalisations below $100m. F...

A quick wrap of the ASX’s key winners and losers on Thursday, August 6. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 851 stocks rose, 506 declined and...

A quick wrap of the ASX’s key winners and losers on Thursday, July 23. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day. Today 798 stocks rose, 500 de...

A quick wrap of the ASX’s key winners and losers on Tuesday, July 7. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 571 stocks rose, 750 declined and 786...

Australian biotechnology company AdAlta (ASX:1AD) says it has received Human Research Ethics Committee (HREC) approval to commence a phase one clinical trial of its lead product candidate, AD-214.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Cochlear’s...

At the turn of the millennium Megan Baldwin, high flying CEO of ophthalmology biotech Opthea (ASX:OPT), had a decision to make: did she take a promising job in Australian academia or leap into the hotbed of innovation, San Francisco, for th...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Shark-based biotech Adalta (ASX:1AD) is one of 17 companies that have won federal government funding. The company’s ‘i-body’ platform is based on the shape of a shark antibody, which is one tenth the size of traditional antibodies. Its lead...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Australian biopharmaceutical company AdAlta (ASX:1AD) has appointed a senior and experienced industry executive as its new CEO and managing director.

FirstWave Cloud Technology (ASX: FCT) has won technology super-aggregator Digital WholeSale Solutions (DWS) as a sales partner in Britain and shares have jumped 13 per cent. FirstWave sells a cyber security platform for cloud content aimed...

Investing in Small-Cap Stocks Biotech is a dynamic and profitable sector for investors. Capital venture in biotech stocks provides great enthusiasm and diversification support to market fans. In general, before investing money in stocks, in...

“History is bunk!’’ declared industrialist Henry Ford, but unfortunately for the oro-mucosal delivery specialist Suda, distancing itself from its corporate past has not been a simple case of cranking up the Model T and hitting the road. In...

Melbourne-based company AdAlta (ASX:1AD) has signed a commercial agreement for its i-body platform with global medical technology firm, GE Healthcare. 

No, its not photoshopped. This ratfish was caught in deep water in northern Norway. It’s no blue whale, but its got enormous eyes to help it see in the darkness below. It may look scary but it is completely harmless — it feeds mainly on cra...

Medical tech stock AdAlta (ASX:1AD) thinks that when it comes to immunisation, what works for sharks can also work for humans. And the company’s technology has caught the eye of global player GE Healthcare. AdAlta announced this morning tha...

Biotech company AdAlta (ASX: 1AD) signed taken a significant towards monetising its proprietary technology after signing a commercial agreement for its i-body platform with US-based medical technology giant, GE Healthcare. However, despite...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...